Look out, Teva. Neurocrine's Ingrezza wins Huntington's disease FDA nod to rival Austedo

With a new FDA approval to rival Teva's Austedo, Neurocrine Biosciences’ Ingrezza is debuting in a treatment area with hundreds of millions of dollars of revenue potential.

Late last week, the FDA approved Ingrezza capsules to treat adults with chorea associated with Huntington’s disease.